Treatment of bone metastasis in prostate cancer: Efficacy of a novel polybisphosphonate

Anticancer Research

Volumn 31, Issue 12, 2011, Pages 4141-4146

  Daubine, Florence ^a   Le Bot, Ronan ^a   Márquez, Marcela ^b   Nilsson, Sten ^b   Schröder, Torbjörn ^b   Holmberg, Anders R ^b  

^a Atlantic Bone Screen   (France)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Bone metastasis; Polybisphosphonate; Prostate cancer

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; POLYBISPHOSPHONATE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE METASTASIS; BONE RADIOGRAPHY; CANCER INHIBITION; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; FOLLOW UP; IN VIVO STUDY; MALE; NONHUMAN; OSSIFICATION; OSTEOCLAST; OSTEOLYSIS; PRIORITY JOURNAL; PROSTATE CANCER; RAT; TREATMENT DURATION; TUMOR GROWTH; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; DIPHOSPHONATES; DISEASE PROGRESSION; DRUG DESIGN; FEMUR; MALE; NEOPLASM METASTASIS; NEOPLASM TRANSPLANTATION; OSTEOLYSIS; PROSTATIC NEOPLASMS; RATS; RATS, SPRAGUE-DAWLEY; TIME FACTORS;

EID: 84855168347     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Buijs JT and van der Pluijm G: Osteotropic cancers: from primary tumor to bone. Cancer Lett 273: 177-193, 2009.
2. Paget S: The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Rev 8: 98-101, 1989.
3. Bussard KM, Gay CV and Mastro AM: The bone microenvironment in metastasis: What is special about bone? Cancer Met Rev 27: 41-55, 2008.
4. Saad F and Sternberg CN: Multidisciplinary management of bone complications in prostate cancer and optimizing outcomes of bisphosphonate therapy. Nature Clin Prac Urol 4: 3-13, 2007.
5. Gralow J and Tripathy D: Managing metastatic bone pain: the role of bisphosphonates. J Pain Symptom Manage 33: 462-472, 2007. (Pubitemid 46482947)
6. Hoesl CE and Altwein JE: Bisphosphonates in advanced prostate and renal cell cancer - current status and potential applications. Urol Int 76: 97-105, 2006. (Pubitemid 43872555)
7. Brown JE and Coleman RE: The role of bisphosphonates in breast cancer: the present and future role of bisphosphonates in the management of patients with breast cancer. Breast Cancer Res 4: 24-29, 2002. (Pubitemid 34097553)
8. Neville-Webbe HL, Evans CA, Coleman RE and Holen I: Mechanisms of the synergistic interaction between the bisphosphonate zoledronic acid and the chemotherapy agent paclitaxel in breast cancer cells in vitro. Tumor Biol 27: 92-103, 2006.
9. Holmberg AR, Lerner U, Alayia A, Al-Mohanna M, Adra C, Márquez M, Meurling L and Nilsson S: Development of a novel poly bisphosphonate conjugate for treatment of skeletal metastasis and osteoporosis. Int J Oncol 37: 563-567, 2010.
10. Steele VE and Lubet RA: The use of animal models for cancer chemoprevention drug development. Semin Oncol 37(4): 327-338, 2010.
11. Rosol TJ, Tannehill-Gregg SH, LeRoy BE, Mandl S and Contag CH: Animal models of bone metastasis. Cancer 97(3 Suppl): 748-757, 2003. (Pubitemid 36125810)
12. Logothetis CJ and Lin SH: Osteoblasts in prostate cancer metastasis to bone. Nat Rev Cancer 5(1): 21-28, 2005. (Pubitemid 40052322)
13. Lamoureux F, Ory B, Battaglia S, Pilet P, Heymann MF, Gouin F, Duteille F, Heymann D and Redini F: Relevance of a new rat model of osteoblastic metastases from prostate carcinoma for preclinical studies using zoledronic acid. Int J Cancer 122(4): 751-760, 2008.
14. Lee MV, Fong EM, Singer FR and Guenette RS: Bisphosphonate treatment inhibits the growth of prostate cancer cells. Cancer Res 61: 2602-2608, 2001. (Pubitemid 32685845)
15. Senaratne SG, Pirianov G, Mansi JL, Arnett TR and Colston KW: Bisphosphonates induce apoptosis in human breast cancer cell lines. Br J Cancer 82(8): 1459-1468, 2000. (Pubitemid 30175914)
16. Daubine F, Le Gall C, Gasser J, Green J and Clézardin P: Antitumor effects of clinical dosing regimes of bisphosphonates in experimental breast cancer bone metastases. J Natl Cancer Inst 99: 322-330, 2007. (Pubitemid 47073494)
17. Wakchoure S, Merrell MA, Aldrich W, Millender-Swain T, Harris KW, Triozzi P and Selander KS: Bisphosphonates inhibit the growth of mesothelioma cells in vitro and in vivo. Clin Cancer Res 12: 2862-2868, 2006.
18. Brown HK and Holen I: Antitumor effects of bisphosphonates-What have we learned from in vivo models? Curr Cancer Drug Targets 9(7): 807-823, 2009.
19. Dearnaley DP, Mason MD, Parmar MKB, Sanders K and Sydes MR: Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PRO4 and PRO5 randomised controlled trials. Lancet Oncol 10: 872-876, 2009.
20. Neville-Webbe HL and Coleman RE: Bisphosphonates and RANK ligand inhibitors for the treatment and prevention of metastatic bone disease. Eur J Cancer 46: 1211-1222, 2010.
21. Firazi K, Carducci M, Smith M, Damião R, Brown J, Karsh L, Milecki P, Shore N, Rader M, Wang H, Jiang Q, Tadros S, Dansey R and Goessl C: Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 377: 813-822, 2011.
22. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, Chin JL, Vinholes JJ, Goas JA and Zheng M: Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 96(11): 879-882, 2004. (Pubitemid 38807610)
23. Meurling L, Márquez M, Nilsson S and Holmberg AR: Polymer-conjugated guanidine is a potentially useful antitumor agent. Int J Oncol 35: 281-285, 2009.